Advaxis Completes Dosing of Vanguard Patient Group in Phase II Cervical Dysplasia Clinical Trial
NORTH BRUNSWICK, N.J.—-Advaxis, Inc., , the live, attenuated Listeria monocytogenes biotechnology company, enrolled and has administered its initial dose to its third patient in its US Food and Drug Administration -approved, phase II clinical trial in cervical intraepithelial neoplasia , commonly known as cervical dysplasia.
Read more on Business Wire via Yahoo! Finance
